BIOMARKERS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease ("COPD") but not manifesting clinical symptoms of COPD; and 2) subjects havin...

Full description

Saved in:
Bibliographic Details
Main Authors BARRERO, CARLOS, A, KELSEN, STEVEN, G, MERALI, SALIM
Format Patent
LanguageEnglish
French
Published 01.11.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease ("COPD") but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring. La présente invention concerne des procédés qui sont basés sur la découverte que le taux plasmatique d'un panel de protéines spécifiques diffère entre deux populations de sujets : 1) sujets à risque de bronchopneumopathie chronique obstructive (« BPCO ») mais ne manifestant pas de symptômes cliniques de BPCO ; et 2) sujets ayant une BPCO très grave. La différence des taux plasmatiques est statistiquement significative pour chaque protéine. L'identification de ces protéines facilite ainsi la détection d'une sensibilité, la détection précoce de la maladie, l'évaluation de la gravité de la maladie, la surveillance de la progression de la maladie, et la surveillance de l'efficacité d'une thérapie.
Bibliography:Application Number: WO2012US27998